Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hjorth

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|January 1, 1992
Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western SwedenM Hjorth, E Holmberg, S Rödjer, et al.
Lakartidningen|December 7, 2000
[High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective]M Hjorth, S Lenhoff, I Turesson, et al.
Pharmacoeconomics|June 6, 1997
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trialE Nord, F Wisløff, M Hjorth, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 17, 2012
Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alumS Axelsson, M Hjorth, J Ludvigsson, et al.
British Journal of Haematology|September 1, 1995
Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centresM Hjorth, E Holmberg, S Rödjer, et al.
Physical Review Letters|October 15, 2008
Medium-mass nuclei from chiral nucleon-nucleon interactionsG Hagen, T Papenbrock, D J Dean, et al.
Controlled Clinical Trials|October 1, 1996
Physicians' attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myelomaM Hjorth, E Holmberg, S Rödjer, et al.
Reports on Progress in Physics. Physical Society (Great Britain)|September 16, 2014
Coupled-cluster computations of atomic nucleiG Hagen, T Papenbrock, M Hjorth-Jensen, et al.
European Journal of Haematology|October 1, 1994
Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study GroupL M Knudsen, E Hippe, M Hjorth, et al.
British Journal of Haematology|February 1, 1990
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western SwedenM Hjorth, L Hellquist, E Holmberg, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|January 1, 1992
Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western SwedenM Hjorth, E Holmberg, S Rödjer, et al.
Lakartidningen|December 7, 2000
[High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective]M Hjorth, S Lenhoff, I Turesson, et al.
Pharmacoeconomics|June 6, 1997
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trialE Nord, F Wisløff, M Hjorth, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 17, 2012
Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alumS Axelsson, M Hjorth, J Ludvigsson, et al.
British Journal of Haematology|September 1, 1995
Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centresM Hjorth, E Holmberg, S Rödjer, et al.
Physical Review Letters|October 15, 2008
Medium-mass nuclei from chiral nucleon-nucleon interactionsG Hagen, T Papenbrock, D J Dean, et al.
Controlled Clinical Trials|October 1, 1996
Physicians' attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myelomaM Hjorth, E Holmberg, S Rödjer, et al.
Reports on Progress in Physics. Physical Society (Great Britain)|September 16, 2014
Coupled-cluster computations of atomic nucleiG Hagen, T Papenbrock, M Hjorth-Jensen, et al.
European Journal of Haematology|October 1, 1994
Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study GroupL M Knudsen, E Hippe, M Hjorth, et al.
British Journal of Haematology|February 1, 1990
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western SwedenM Hjorth, L Hellquist, E Holmberg, et al.
Pageof 6